Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Zhibo Zhang(Nanjing Drum Tower Hospital), Jinliang Wang(Tianjin University)
Cited by 54
Related Papers
Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
|Frontiers in Oncology|2021|125
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
|Clinical Medicine Insights Oncology|2021|64
Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer
|Cancer Immunology Immunotherapy|2019|45